TY - JOUR T1 - Targeting a highly repetitive genomic sequence for sensitive and specific molecular detection of the filarial parasite <em>Mansonella perstans</em> from human blood and mosquitoes JF - medRxiv DO - 10.1101/2022.06.29.22277064 SP - 2022.06.29.22277064 AU - Nils Pilotte AU - Tamara Thomas AU - Michael Zulch AU - Allison R. Sirois AU - Corrado Minetti AU - Lisa Reimer AU - Steven A. Williams AU - Lori Saunders Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/06/30/2022.06.29.22277064.abstract N2 - Background Mansonella perstans is among the most neglected of the neglected tropical diseases, and is believed to cause more human infections than any other filarial pathogen in Africa. Based largely upon assumptions of limited infection-associated morbidity, this pathogen remains understudied, and many basic questions pertaining to its pathogenicity, distribution, prevalence, and vector-host relationships remain unanswered. However, in recent years, mounting evidence of the potential for increased Mansonella infection-associated disease has sparked a renewal in research interest. This, in turn, has produced a need for improved diagnostics, capable of providing more accurate pictures of infection prevalence, pathogen distribution, and vector-host interactions.Methodology/Principal Findings Utilizing a previously described pipeline for the discovery of optimal molecular diagnostic targets, we identified a repetitive DNA sequence, and developed a corresponding assay, which allows for the sensitive and species-specific identification of M. perstans in human blood samples. Testing also demonstrated the ability to utilize this assay for the detection of M. perstans in field-collected mosquito samples. When testing both sample types, our repeat-targeting index assay outperformed a ribosomal sequence-targeting reference assay, facilitating the identification of additional M. perstans-positive samples falsely characterized as “negative” using the less sensitive detection method.Conclusions/Significance Through the development of an assay based upon the systematic identification of an optimal DNA target sequence, our novel diagnostic assay will provide programmatic efforts with a sensitive and specific testing platform that is capable of accurately mapping M. perstans infection and determining prevalence. Furthermore, with the added ability to identify the presence of M. perstans in mosquito samples, this assay will help to define our knowledge of the relationships that exist between this pathogen and the various geographically relevant mosquito species, which have been surmised to represent potential secondary vectors under certain conditions. Detection of M. perstans in mosquitoes will also demonstrate proof-of-concept for the mosquito-based monitoring of filarial pathogens not vectored primarily by mosquitoes, an approach expanding opportunities for integrated surveillance.Author Summary Infection with Mansonella perstans remains exceedingly common in many of the world’s tropical and sub-tropical regions. However, M. perstans is largely understudied due to the long-held belief that this pathogen is of little clinical significance. However, in recent years, many within the research community have begun to advocate for the increased study of this pathogen, pointing to evidence of mansonellosis-associated disease morbidity, the potential for Mansonella spp. to confound diagnostic testing for other pathogens, and the possibility for co-infections with M. perstans to impact disease progression and treatment outcomes for other infections. As a result of this growing appreciation of the importance of M. perstans, there exists a need for improved diagnostic options, capable of providing researchers with the tools required to accurately and effectively map infection, explore the pathogen-vector relationship, and determine pathogen prevalence. In response to these needs, we have developed a novel real-time PCR assay targeting a highly repetitive DNA sequence within the M. perstans genome. This index assay outperformed a ribosomal-sequence targeting reference assay when comparatively testing both human blood and field-collected mosquito samples. As such, this assay will provide researchers with an improved tool for the identification of M. perstans as part of various operational research efforts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by an award to NP from the Bill and Melinda Gates Foundation [Grand Challenges Explorations Phase II investment number OPP1154992 "Sustainable, Low-cost Xenomonitoring for Lymphatic Filariasis and Malaria via Highthroughput Screening of Mosquito Excreta/Feces"] and by an award to LJR from the Global Challenges Research Fund, funded by the MRC, AHRC, BBSRC, ESRC, and NERC [grant number MR/P025285/1]. Additional support for this work was provided to LJS by the Blakeslee Fund for Genetics Research at Smith College. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Liverpool School of Tropical Medicine Ethics Committee gave ethical approval for this work. The Council for Scientific and Industrial Research, Accra, Ghana gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. ER -